Answers are grounded in this paper and cite their sources.
The study revealed the differential ability of cefepime/taniborbactam and cefepime/zidebactam in tackling carbapenemase-producing Indian clinical isolates that also harbored additional mechanisms of resistance. NDM-expressing E. coli with 4-amino-acid insert in PBP3 are predominately resistant to cefepime/taniborbactam, while the β-lactam enhancer mechanism-based cefepime/zidebactam showed consistent activity against single- or dual-carbapenemase-producing isolates including E. coli with PBP3 inserts.
No takes yet. Share an insight, caveat, or question.
Bakthavatchalam et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: